Therapeutic Pipeline
NucleoTech builds its internal therapeutic programs by pairing clinically validated drug backbones with proprietary BrainPortal™ carriers, taking therapeutics with proven biology elsewhere in the body and enabling them to reach the brain for the first time. In parallel, NucleoTech is open to partnering with companies developing new drug candidates from early stages, providing carrier solutions that are integrated into the program from the ground up.
Together these two models define NucleoTech’s therapeutic strategy: independently advancing high-conviction programs built on de-risked biology, while extending the reach of the BrainPortal™ platform to partners who need brain delivery as a core part of their development path.
Therapeutic pipeline
Our Approach
NucleoTech's internal programs follow a repeatable model. We identify CNS indications where a therapeutic with strong, well-characterized biology in the periphery is blocked from the brain by the BBB. We prioritize drug backbones that are off-patent and in the public domain, ensuring clean IP and freedom to operate from the outset. We then conjugate that therapeutic to a BrainPortal™ carrier, validate delivery and efficacy through our direct in vivo platform, and advance the program through preclinical development toward IND filing and early clinical stages.
This approach is deliberately de-risked. The therapeutic biology is already established; what we are solving is the delivery problem, not the target biology. Combined with the speed and precision of our direct in vivo platform, this allows NucleoTech to move programs forward faster and with greater confidence than a conventional CNS drug development program.
Program 1: HER2+ Brain Metastases
HER2-targeted therapies have transformed outcomes for HER2-positive cancer patients, but their reach stops at the blood-brain barrier. When HER2+ cancers spread to the brain, as they frequently do, the same antibody drugs that are highly effective in the body become largely ineffective in the brain. Patients are left without access to the very treatments that work for their disease.
NucleoTech’s HER2+ brain metastases program pairs a brain-deliverable Herceptin backbone with a BrainPortal™ carrier, enabling the established therapeutic mechanism of HER2-targeted antibody therapy to reach the brain for the first time. The drug backbone is off-patent and well-characterized. BrainPortal™ carriers solve the delivery problem.
Program 2: Progressive Multiple Sclerosis
Anti-CD20 therapies have demonstrated meaningful clinical benefit in multiple sclerosis, but progressive MS, particularly the primary progressive form, remains one of the most difficult CNS conditions to treat. Existing CD20-targeting antibodies are largely excluded from the brain by the blood-brain barrier, limiting their ability to address the neuroinflammatory processes driving disease progression in the CNS.
NucleoTech’s progressive MS program pairs a brain-deliverable CD20-targeting antibody backbone with a BrainPortal™ carrier, bringing the established mechanism of anti-CD20 therapy directly to the site of disease in the CNS. As with our HER2+ program, the biology is proven. What was missing was a way across the barrier.
